Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.
P. G. G. Richardson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis
P. Moreau
No relevant relationships to disclose
A. J. Jakubowiak
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb; Celgene
T. Facon
Consultant or Advisory Role - Bristol-Myers Squibb
S. Jagannath
Consultant or Advisory Role - Celgene; Merck; Millennium
R. Vij
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene
Honoraria - Bristol-Myers Squibb; Celgene
D. E. Reece
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Ortho; Merck; Novartis; Otsuka
Research Funding - Bristol-Myers Squibb; Celgene; Janssen-Ortho; Johnson & Johnson; Merck; Novartis
D. White
No relevant relationships to disclose
M. Raab
No relevant relationships to disclose
L. Benboubker
No relevant relationships to disclose
J. Rossi
Consultant or Advisory Role - Celgene; Sanofi
Honoraria - Celgene; Sanofi
C. Tsao
Employment or Leadership Position - Abbott Laboratories
T. Parli
Employment or Leadership Position - Abbott Biotherapeutics
Stock Ownership - Abbott Laboratories
D. M. Berman
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
A. K. Singhal
Employment or Leadership Position - Abbott Laboratories
S. Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx